NCCN and Polish oncology groups to adapt NCCN Guidelines for Poland

The fight against cancer is global. Our focus must be as well.

Today, our world is small. It feels smaller all the time. In a few hours we can get to any point on the globe.

February 21, 2025

World Cancer Day 2025: A symbol of personal and collective uncertainty

My entire life I was told to respectfully question anything and everything, because questions equal answers, which provide understanding and thereby comfort—even with the uncomfortable. It’s simply in my DNA.

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The document provides guidance on testing for inherited genetic mutations that can raise the risk of cancer.

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

The National Comprehensive Cancer Network included circulating tumor DNA testing in their Clinical Practice Guidelines in Oncology for diffuse large B-cell lymphoma. This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care.

January 17, 2025

Vol.51 No.02

In Brief

Asia Society Policy Institute, Cure4Cancer call for expansion of U.S.-Australia cancer alliance

Asia Society Policy Institute’s Center for China Analysis and Cure4Cancer jointly published “Advancing Global Health Equity: Expanding the U.S.-Australia Cancer Alliance Toward an Asia-Pacific Collaborative Effort to Save Millions of Lives.”

December 06, 2024

Vol.50 No.45

Clinical Roundup

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.

November 22, 2024

Vol.50 No.44